Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | CPX-351 and gemtuzumab ozogamicin in R/R AML and MDS

Jayastu Senapati • 11 Dec 2022
ASH 2022
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Antibodies CPX-351 Gemtuzumab ozogamicin Venetoclax

Jayastu Senapati, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents updates from a Phase II trial (NCT03672539) investigating CPX-351 in combination with gemtuzumab ozogamicin (GO) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and post-hypomethylating agent failure high-risk myelodysplastic syndromes (HR-MDS). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jayastu Senapati

1:42
ATG-based immunosuppressive therapy in elderly patients with aplastic anemia
Jayastu Senapati • 11 Dec 2022
1:17
Decitabine, venetoclax and ponatinib in patients with advanced CML and Ph+ AML
Jayastu Senapati • 11 Nov 2022
1:23
The effect of splicing factor gene mutations on the outcomes of patients with AML
Jayastu Senapati • 11 Dec 2022
1:37
Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALL
Jayastu Senapati • 11 Dec 2022

Related Videos

8:40
Investigating PP2A-based therapeutic strategies for KMT2A-rearranged acute leukemia
Maria Teresa Esposito • 25 Apr 2024
1:55
Factors to consider when choosing a treatment option for patients with CLL
Piers Patten • 28 Apr 2024
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals